Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Vaxcyte, Inc.

< Previous 1 2 Next >
Vaxcyte Appoints Jacks Lee to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX STRO
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Second Quarter 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the Jefferies Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the BofA Securities 2023 Health Care Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Pricing of $500 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Present at Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Pricing of $600 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.